Journal of Global Infectious Diseases

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 6  |  Issue : 3  |  Page : 114--117

Anti tuberculosis drug resistance in west of Iran


Parviz Mohajeri1, Baharak Norozi2, Sara Atashi3, Abbas Farahani2 
1 Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
3 West Tuberculosis Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Correspondence Address:
Parviz Mohajeri
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah
Iran

Background and Objective: Mycobacterium tuberculosis has developed resistance to antituberculosis drugs and becoming a major and alarming public health problem in worldwide. This study was aimed to determine antituberculosis drug resistance rate and to identify multidrug resistant tuberculosis (MDR-TB) in West of Iran. Materials and Methods: Of 130 samples were included between December 2011 and July 2012 in the study from that 112 cases were M. tuberculosis. The proportional method was carried out according to the Clinical and Laboratory Standards Institute on Lowenstein-Jensen against isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, para aminosalicylic acid, ethionamide, cycloserine (CYC). The microdilution method was carried out using 7H9 broth with 96 well-plates. Results: From 112 isolates, resistance was observed to isoniazid 18 (16.07%), rifampicin 16 (14.28%), streptomycin 25 (22.32%), ethambutol 15 (13.39%), pyrazinamide 27 (24.10%), para aminosalicylic acid 19 (16.96%), CYC 4 (3.57%), and ethionamide 14 (12.5%) cases. 16 isolates were MDR. Conclusion: The high prevalence of MDR-TB in our study is assumed to be due to recent transmission of drug-resistant strains. Overall, the rate of drug resistance in our study was high, which is in line with findings of some high-burden countries. Hence that early case detection, rapid drug susceptibility testing, and effective anti-TB treatment is necessary.


How to cite this article:
Mohajeri P, Norozi B, Atashi S, Farahani A. Anti tuberculosis drug resistance in west of Iran.J Global Infect Dis 2014;6:114-117


How to cite this URL:
Mohajeri P, Norozi B, Atashi S, Farahani A. Anti tuberculosis drug resistance in west of Iran. J Global Infect Dis [serial online] 2014 [cited 2021 Dec 6 ];6:114-117
Available from: https://www.jgid.org/article.asp?issn=0974-777X;year=2014;volume=6;issue=3;spage=114;epage=117;aulast=Mohajeri;type=0